 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 11/20/2006 | | | | Nymox Pursuing New Approaches to an Old Disease
topic: R&D: Alzheimer's Disease Treatments
November 20, 2006: Nymox is taking innovative and unique approaches to the diagnosis and treatment of Alzheimer's disease. It is widely recognized that new methods of treating and diagnosing Alzheimer's disease are urgently needed in the face of an impending world-wide epidemic of Alzheimer’s disease. |
| 11/17/2006 | | | | Nymox Product a Tool for Smoking Cessation Efforts
topic: Tobacco Exposure Tests
November 17, 2006: November 16 is the American Cancer Society’s Great American Smokeout, when smokers across the U.S. are encouraged to butt out for the day and hopefully for good. Nymox offers its NicAlert™ products which allow concerned individuals the ability to perform an on-the-spot evaluation of smoking status. NicAlert™ has been successfully used in many studies of smoking status and in smoking cessation and harm reduction campaigns in the U.S. and in Europe and is currently being used in a large smoking cessation study in collaboration with g Nostics Ltd. in the U.K. |
| 11/13/2006 | | | | Nymox Reports Third Quarter 2006 Financial Results
topic: Financial
November 13, 2006: Nymox Pharmaceutical Corporation announced today its financial results for the third quarter of 2006. |
| 11/10/2006 | | | | Statin Drugs Gain Traction as Potential Treatment for Alzheimer’s Disease
topic: Statins and Alzheimer's Disease
November 10, 2006: Statins, the widely used cholesterol drugs with a global market over $25 billion, are gaining wide attention as a potential new way of treating Alzheimer’s disease (AD) according to recent reports. Nymox holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD, including for patients at risk for AD because of vascular-related risk factors or disease.
|
| 11/03/2006 | | | | Nymox Pharmaceutical to Present at the 29th Annual Westergaard SmallCap Conference
topic: Financial
November 3, 2006: Nymox announced today that Dr. Paul Averback, CEO of Nymox Pharmaceutical, will present at the 29th Annual Westergaard SmallCap Conference on Monday, November 6, 2006. |
| 10/31/2006 | | | | Nymox Pursuing Plans for Marketing Partnerships for Its NX-1207 BPH Drug
topic: Financial
October 31, 2006: Nymox announced today that the Company is in discussions with potential marketing partners for the Company’s NX-1207 drug for the treatment of benign prostatic hyperplasia (BPH), following the successful completion of a placebo-controlled, double-blind, multi-center Phase 2 trial. |
| 10/17/2006 | | | | Demand for Enlarged Prostate Treatments Expected to Rise Sharply
topic: R&D: BPH (enlarged prostate) Treatments
October 17, 2006: Changing demographics and attitudes towards health will drive the demand for new and effective treatments for enlarged prostate in the maturing male baby boomer population. Nymox has developed NX-1207, an innovative new treatment for BPH. The company's recently completed Phase 2 trial showed positive efficacy and safety results for NX-1207. |
| 10/04/2006 | | | | Journal of the American Medical Directors Association Publishes Positive Independent National Study of Nymox's AlzheimAlert™ Urine Test For Alzheimer's Disease
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
October 4, 2006: Nymox announces the publication of a peer-reviewed report on the successful results
of a multi-center double blind independent clinical study of the Company's urinary
AlzheimAlert™ test in the Journal of the American Medical Directors Association. |
| 09/27/2006 | | | | Nymox Targets E. Coli Food Contamination with Innovative New Products
topic: R&D: E coli and Other Antibacterial Treatments
September 27, 2006: Nymox is developing innovative new products to combat the serious threat E. coli O157:H7 contamination poses to the food supply system and to public health. |
| 09/22/2006 | | | | Nymox Pharmaceutical to Present at the Noble Financial Small Cap Conference
topic: Financial
September 22, 2006: Nymox announced today that Dr. Paul Averback, President and CEO of Nymox Pharmaceutical,
will present at the Noble Financial Small Cap Conference in Charlotte, NC on September 26. |
|